Deflazacort

CLINICAL USE

Glucocorticoid:Suppression of inflammatory and allergic disorders

DOSE IN NORMAL RENAL FUNCTION

3–18 mg daily(Acute disorders up to 120 mg daily initially)

PHARMACOKINETICS

Molecular weight :441.5

%Protein binding :40

%Excreted unchanged in urine : 70

Volume of distribution (L/kg) :1.2

half-life – normal/ESRD (hrs) :1.1–1.9/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAntibacterials: metabolism accelerated by rifampicin; metabolism possibly inhibited by erythromycinAnticoagulants: efficacy of coumarins may be alteredAnti-epileptics: metabolism accelerated by carbamazepine, barbiturates, phenytoin and primidoneAntifungals: increased risk of hypokalaemia with amphotericin – avoid concomitant use; metabolism possibly inhibited by itraconazole and ketoconazole. Antivirals: concentration possibly increased by ritonavirCiclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids; increased half-life of deflazacortCytotoxics: increased risk of haematological toxicity with methotrexateDiuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diureticsVaccines: high dose corticosteroids can impair immune response to vaccines; avoid concomitant use with live vaccines

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

6 mg of deflazacort is equivalent to 5 mg prednisolone.

Tags: post-by-auto-php